Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 0.57%

Ligand Pharmaceuticals reported a strong EPS performance, significantly exceeding expectations, which contributed to a modest stock increase of 0.57%. However, the lack of revenue data and forward guidance leaves some uncertainty about the company's future performance. Investors may be encouraged by the positive EPS surprise but will likely look for more information in future updates.